| 12.39 -0.76 (-5.78%) | 10-10 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 16.94 | 1-year : | 19.1 |
| Resists | First : | 14.5 | Second : | 16.36 |
| Pivot price | 12.74  |
|||
| Supports | First : | 11.5 | Second : | 9.57 |
| MAs | MA(5) : | 12.97  |
MA(20) : | 13.28 |
| MA(100) : | 0 | MA(250) : | 0 | |
| MACD | MACD : | -0.5 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 38.4 |
D(3) : | 39.4 |
| RSI | RSI(14): 43.1 |
|||
| 52-week | High : | 16.36 | Low : | 11.5 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ SI ] has closed above bottom band by 40.4%. Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 13.35 - 13.4 | 13.4 - 13.44 |
| Low: | 12.67 - 12.73 | 12.73 - 12.79 |
| Close: | 13.04 - 13.14 | 13.14 - 13.24 |
Shoulder Innovations, Inc. manufactures medical devices. It has developed a shoulder replacement system. The company was founded by Stephen B. Gunther and Michael DeVries in 2009 and is headquartered in Grand Rapids, MI.
Mon, 22 Sep 2025
Bone-Preserving InSet 70 Shoulder Implant: Shoulder Innovations' Latest Innovation for Arthritis Treatment - Stock Titan
Mon, 22 Sep 2025
Shoulder Innovations Announces Full Commercial Launch of the InSet™ 70 Humeral Stem - PR Newswire
Fri, 19 Sep 2025
Insider Buying: Shoulder Innovations (NYSE:SI) CEO Purchases 2,000 Shares of Stock - MarketBeat
Tue, 09 Sep 2025
Shoulder Innovations Reports Second Quarter 2025 Financial Results - PR Newswire
Sat, 06 Sep 2025
Shoulder Innovations Stock Jumps 8% On NYSE Debut - MSN
Mon, 25 Aug 2025
Shoulder Innovations stock initiated with Buy rating by BTIG - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Specialties
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|